Back HIV/AIDS

HIV / AIDS

IAS 2013: Stem Cell Transplant Patients Remain HIV-Free [VIDEO]

Two Boston men with HIV who received bone marrow transplants after a milder conditioning chemotherapy regimen continued to have undetectable virus 7 and 15 weeks after undergoing experimental treatment interruption, researchers reported at the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) this week in Kuala Lumpur.

alt

IAS 2013: Study Supports WHO Second-line HIV Treatment Guidelines for Resource-limited Countries

A second-line regimen consisting of a protease inhibitor (PI) plus 2 nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) led to good outcomes for people with HIV in Africa after initial regimen failure, according to data from the EARNEST study presented at the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) this week in Kuala Lumpur. A NRTI-sparing regimen with raltegravir did not work significantly better, and PImonotherapy was inferior.

alt

IAS 2103: Dolutegravir Beats Raltegravir for Treatment-experienced HIV Patients [VIDEO]

The once-daily HIV integrase inhibitor dolutegravir demonstrated better efficacy than twice-daily raltegravir (Isentress), with fewer study withdrawal due to virological failure and less drug resistance, according to data from the SAILING trial presented at the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) this week in Kuala Lumpur.

alt

IAS 2013: Boston Stem Cell Transplant Recipients Now Controlling HIV Off Treatment

Two people with HIV who received stem cell transplants to treat lymphoma are now controlling HIV replication without antiretroviral medication in the early weeks of treatment interruption, following the discovery that both had experienced loss of detectable HIV DNA, researchers from Boston reported Wednesday at the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) in Kuala Lumpur.alt

IAS 2013: Reduced Efavirenz Dose Suppresses HIV as Well as Standard Dose

Lowering the dosage of efavirenz (Sustiva) from 600 to 400 mg in an antiretroviral regimen did not compromise efficacy, and has the potential to substantially reduce treatment cost, according to data from the ENCORE1 study presented at the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) this week in Kuala Lumpur.

alt

IAS 2013: iPrEx Participants Interested in Continuing HIV Pre-exposure Prophylaxis [VIDEO]

A majority of participants in an extension of the iPrEx pre-exposure prophylaxis (PrEP) trial said they would like ongoing open-label access to Truvada for HIV prevention, researchers reported at the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) this week in Kuala Lumpur.

alt

IAS 2013: Dolutegravir Superior to Raltegravir for Treatment-experienced People with HIV

The once-daily HIV integrase inhibitor dolutegravir demonstrated better efficacy than twice-daily raltegravir for previously treated people with HIV, with fewer study withdrawals due to virological failure and less emergent drug resistance, researchers reported at the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) this week in Kuala Lumpur. Results were published concurrently in the July 3, 2013, online edition of The Lancet.

alt